Monitor the conference call at 8:30am ET for additional detail and FDA feedback. Stock could react positively given compelling efficacy in a high-need indication, but early-stage data (n=3) warrants caution. Track enrollment updates and any FDA IDE expansion announcements.
Price Chart
Executive Summary
Alpha Tau announced interim results from its U.S. Alpha DaRT recurrent glioblastoma trial (REGAIN) showing 100% local disease control and 67% complete response rate in the first three patients, with one resolved grade 3 SAE. The data is early but highly promising for a deadly cancer with limited treatment options, potentially de-risking the ongoing trial and expanding Alpha Tau's pipeline.
Key Facts
- 100% local disease control in first three recurrent GBM patients treated with Alpha DaRT
- 67% complete response rate: two patients had total disappearance of enhancing tumor lesions
- One grade 3 SAE (seizure with temporary paralysis) resolved with steroids; no unanticipated SAEs
- FDA requested interim safety analysis before expanding IDE; results support trial continuation
- Trial enrollment expected up to 10 U.S. patients; primary endpoint is feasibility and safety
Financial Impact
No financial figures disclosed; pre-revenue stage. Positive clinical data may increase probability of regulatory success and partnership value.
Risk Factors
- Very small sample size (n=3) limits statistical reliability
- Alpha DaRT not yet approved for any indication; regulatory path uncertain
- Company has limited cash runway per prior 20-F; potential dilution risk
- Historical stock performance on positive news has been weak (previous high-score reports led to declines)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-054165 |
| Document: ea0290048-6k_alpha.htm | 0001213900-26-054165 |
| Document: 0001213900-26-054165-index-headers.html | 0001213900-26-054165 |
| Document: 0001213900-26-054165-index.html | 0001213900-26-054165 |
| Document: 0001213900-26-054165.txt | 0001213900-26-054165 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access